Differential proteomic analysis of pathway biomarkers in human breast cancer by integrated bioinformatics

Fu-Jun,Liu; Shao-Hua,Jin; Xiao-Fang,Shen

doi:10.3892/ol.2012.881

Differential proteomic analysis of pathway biomarkers in human breast cancer by integrated bioinformatics

Authors:
- Liu Fu-Jun
- Jin Shao-Hua
- Shen Xiao-Fang
View Affiliations

Affiliations: Central Laboratory, Yu-Huang-Ding Hospital/Qingdao University, Yantai, Shandong 264000, P.R. China, Central Laboratory, Yu-Huang-Ding Hospital/Qingdao University, Yantai, Shandong 264000, P.R. China, Reproduction Medical Center, Yu-Huang-Ding Hospital/Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: August 24, 2012 https://doi.org/10.3892/ol.2012.881
Pages: 1097-1103

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to better understand the altered functional modules in breast cancer at pathway and network levels. An integrated bioinformatics analysis of differentially expressed proteins in human breast cancer was performed. Breast cancer protein profiles were constructed by data mining proteins in literature and public databases, including 1031 proteins with 153 secretory and 69 cell surface proteins. An experimental investigation was performed by two-dimensional electrophoresis, and 4 proteins were further validated by western blotting. Enriched bioinformatics functions were clustered. This study may be used as a reference in further studies to help identify the underlying biological interactions associated with breast cancer and discover potential cancer targets.

View Figures

View References

1.	E WarnerClinical practice. Breast-cancer screeningN Engl J Med36510251032201110.1056/NEJMcp110154021916640
2.	C AggarwalN SomaiahGR SimonBiomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?J Natl Compr Canc Netw8822832201020679541
3.	Y TanSY MaFQ WangHP MengC MeiA LiuHR WuProteomic-based analysis for identification of potential serum biomarkers in gallbladder cancerOncol Rep26853859201121687958
4.	MS Abu-AsabM ChaouchiS AlesciS GalliM LaassriAK CheemaF AtoufJ VanMeterH AmriBiomarkers in the age of omics: time for a systems biology approachOMICS15105112201110.1089/omi.2010.002321319991
5.	BK DunnPD WagnerD AndersonP GreenwaldMolecular markers for early detectionSemin Oncol37224242201010.1053/j.seminoncol.2010.05.00720709207
6.	JA LudwigJN WeinsteinBiomarkers in cancer staging, prognosis and treatment selectionNat Rev Cancer5845856200510.1038/nrc173916239904
7.	II WistubaJG GelovaniJJ JacobySE DavisRS HerbstMethodological and practical challenges for personalized cancer therapiesNat Rev Clin Oncol8135141201110.1038/nrclinonc.2011.221364686
8.	S Schmitz-SpankeAW RettenmeierProtein expression profiling in chemical carcinogenesis: a proteomic-based approachProteomics11644656201110.1002/pmic.20100040321246732
9.	TY LauDP O’ConnorDJ BrennanMJ DuffySR PenningtonWM GallagherBreast cancer proteomics: clinical perspectivesExpert Opin Biol Ther7209219200710.1517/14712598.7.2.20917250459
10.	H HondermarckC TastetI El Yazidi-BelkouraRA ToillonX Le BourhisProteomics of breast cancer: the quest for markers and therapeutic targetsJ Proteome Res714031411200810.1021/pr700870c18311906
11.	D BöhmK KellerN WehrweinA LebrechtM SchmidtH KölblFH GrusSerum proteome profiling of primary breast cancer indicates a specific biomarker profileOncol Rep2610511056201121837365
12.	M KadowakiT SangaiT NagashimaM SakakibaraH YoshitomiS TakanoK SogawaH UmemuraK FushimiY NakataniF NomuraM MiyazakiIdentification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approachJ Cancer Res Clin Oncol13711051115201110.1007/s00432-010-0974-921253761
13.	B BalluffM ElsnerA KowarschS RauserS MedingC SchuhmacherM FeithK HerrmannC RöckenRM SchmidH HöflerA WalchMP EbertClassification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifierJ Proteome Res963176322201010.1021/pr100573s21058730
14.	TC LaiHC ChouYW ChenTR LeeHT ChanHH ShenWT LeeST LinYC LuCL WuHL ChanSecretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresisJ Proteome Res913021322201010.1021/pr900825t20052998
15.	HJ IssaqTJ WaybrightTD VeenstraCancer biomarker discovery: Opportunities and pitfalls in analytical methodsElectrophoresis32967975201110.1002/elps.20100058821449066
16.	B WeigeltL PusztaiA AshworthJS Reis-FilhoChallenges translating breast cancer gene signatures into the clinicNat Rev Clin Oncol95864201110.1038/nrclinonc.2011.12521878891
17.	CL SawyersThe cancer biomarker problemNature452548552200810.1038/nature0691318385728
18.	CM SchlotterU VogtH AllgayerB BrandtMolecular targeted therapies for breast cancer treatmentBreast Cancer Res10211200810.1186/bcr211218671839
19.	H MukaiTargeted therapy in breast cancer: current status and future directionsJpn J Clin Oncol40711716201010.1093/jjco/hyq03720382634
20.	C Bernard-MartyF LebrunA AwadaMJ PiccartMonoclonal antibody-based targeted therapy in breast cancer: current status and future directionsDrugs6615771591200610.2165/00003495-200666120-0000416956305
21.	SJ LiM PengH LiBS LiuC WangJR WuYX LiR ZengSys-BodyFluid, a systematical database for human body fluid proteome researchNucleic Acids Res37D907D912200910.1093/nar/gkn84918978022
22.	JP da CunhaPA GalanteJE de SouzaRF de SouzaPM CarvalhoDT OharaRP MouraSM Oba-ShinjaSK MarieWA Silva JrBioinformatics construction of the human cell surfaceomeProc Natl Acad Sci1061675216757200919805368
23.	J LiF LiuH WangX LiuJ LiuN LiF WanW WangC ZhangS JinJ LiuP ZhuY LiuSystematic mapping and functional analysis of a family of human epididymal secretory sperm-located proteinsMol Cell Proteomics925172528201010.1074/mcp.M110.00171920736409
24.	HF DvorakVM WeaverTD TlstyG BergersTumor microenvironment and progressionJ Surg Oncol103468474201110.1002/jso.2170921480238
25.	RA GatenbyRJ GilliesWhy do cancers have high aerobic glycolysis?Nat Rev Cancer4891899200410.1038/nrc147815516961
26.	WH KoppenolPL BoundsCV DangOtto Warburg’s contributions to current concepts of cancer metabolismNat Rev Cancer113253372011
27.	H BandoM ToiK KitadaM KoikeGenes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231Biomed Pharmacother57333340200310.1016/S0753-3322(03)00098-214568227
28.	M OsakiM OshimuraH ItoPI3K-Akt pathway: its functions and alterations in human cancerApoptosis9667676200410.1023/B:APPT.0000045801.15585.dd15505410
29.	SE GhayadPA CohenInhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patientsRecent Pat Anticancer Drug Discov52957201010.2174/15748921078970220819751211
30.	RZ OrlowskiEC DeesThe role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancerBreast Cancer Res517200310.1186/bcr46012559038
31.	S RossiM LodaThe role of the ubiquitination-proteasome pathway in breast cancer: use of mouse models for analyzing ubiquitination processesBreast Cancer Res51622200310.1186/bcr54212559040
32.	S LipkowitzThe role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancerBreast Cancer Res5815200310.1186/bcr54112559039
33.	PF McAuliffeF Meric-BernstamGB MillsAM Gonzalez-AnguloDeciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesisClin Breast Cancer10S59S65201010.3816/CBC.2010.s.01321115423
34.	AP StruckhoffMK RanaRA WorthylakeRhoA can lead the way in tumor cell invasion and metastasisFront Biosci1619151926201110.2741/383021196273
35.	S SengHK AvrahamS JiangS YangM SekineN KimelmanH LiS AvrahamThe nuclear matrix protein, NRP/B, enhances Nrf2-mediated oxidative stress responses in breast cancer cellsCancer Res6785968604200710.1158/0008-5472.CAN-06-378517875699
36.	TA MartinMD MasonWG JiangTight junctions in cancer metastasisFront Biosci16898936200110.2741/3726
37.	SH KimJ TurnbullS GuimondExtracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptorJ Endocrinol209139151201110.1530/JOE-10-037721307119
38.	BP WijnhovenWN DinjensM PignatelliE-cadherincatenin cell-cell adhesion complex and human cancerBr J Surg879921005200010.1046/j.1365-2168.2000.01513.x10931041
39.	G BerxF Van RoyThe E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progressionBreast Cancer Res3289293200110.1186/bcr30911597316
40.	C TanP CostelloJ SangheraD DominguezJ BaulidaAG de HerrerosS DedharInhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC−/− human colon carcinoma cellsOncogene20133140200111244511
41.	V BravouG KlironomosE PapadakiS TaravirasJ VarakisILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathwayJ Pathol2089199200610.1002/path.186016278819
42.	V CortezBC NairD ChakravartyRK VadlamudiIntegrin-linked kinase 1: role in hormonal cancer progressionFront Biosci (Schol Ed)3788796201110.2741/s18721196412
43.	A GrigoriadisOL CaballeroKS HoekL da SilvaYT ChenSJ ShinAA JungbluthLD MillerD CloustonJ CebonLJ OldSR LakhaniAJ SimpsonAM NevilleCT-X antigen expression in human breast cancerProc Natl Acad Sci1061349313498200910.1073/pnas.090684010619651608
44.	YM HusseinAF GharibRL EtewaAS El-ShalME Abdel-GhanyWH ElsawyThe melanoma-associated antigen-A3, -A4 genes: relation to the risk and clinicopathological parameters in breast cancer patientsMol Cell Biochem351261268201110.1007/s11010-011-0734-421264495